Relative Value Partners Group LLC Sells 161 Shares of Johnson & Johnson (NYSE:JNJ)

Relative Value Partners Group LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,004 shares of the company’s stock after selling 161 shares during the quarter. Relative Value Partners Group LLC’s holdings in Johnson & Johnson were worth $941,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of JNJ. Keener Financial Planning LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at $40,000. WFA Asset Management Corp increased its position in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 97 shares during the last quarter. Disciplined Equity Management Inc. purchased a new stake in Johnson & Johnson during the fourth quarter valued at $45,000. Altshuler Shaham Ltd increased its position in Johnson & Johnson by 37.8% during the third quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock valued at $49,000 after acquiring an additional 87 shares during the last quarter. Finally, Pacific Capital Wealth Advisors Inc. purchased a new stake in Johnson & Johnson during the fourth quarter valued at $61,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of analyst reports. Morgan Stanley reduced their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, May 6th. Bank of America reduced their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Finally, The Goldman Sachs Group started coverage on Johnson & Johnson in a research report on Thursday. They issued a “neutral” rating and a $160.00 price target for the company. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Check Out Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $146.67 on Friday. The stock has a 50 day moving average of $150.28 and a 200 day moving average of $154.98. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The firm has a market cap of $352.99 billion, a PE ratio of 9.14, a PEG ratio of 2.44 and a beta of 0.55. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.68 earnings per share. On average, research analysts expect that Johnson & Johnson will post 10.64 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.